LPS-enhanced glucose-stimulated insulin secretion is normalized by resveratrol

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Nøhr, Mark K ^a,b   Dudele, Anete ^a   Poulsen, Morten M ^a,b   Ebbesen, Lene H ^b   Radko, Yulia ^c   Christensen, Lars P ^c   Jessen, Niels ^b   Richelsen, Bjørn ^a,b   Lund, Sten ^a,b   Pedersen, Steen B ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPOPOLYSACCHARIDE; RESVERATROL; ANTIOXIDANT; GLUCOSE BLOOD LEVEL; INSULIN; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; EPIDIDYMIS FAT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEPATITIS; INSULIN METABOLISM; INSULIN RELEASE; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; MACROPHAGE; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; SPLENOMEGALY; SUBCUTANEOUS FAT; ADIPOSE TISSUE; ANALYSIS; ANIMAL; BODY WEIGHT; C57BL MOUSE; CHEMISTRY; CYTOLOGY; EPIDIDYMIS; GENE EXPRESSION PROFILING; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INFLAMMATION; INSULIN RESISTANCE; LEUKOCYTE; LIVER; OBESITY; OSMOSIS; PATHOLOGY; PATHOPHYSIOLOGY; SECRETION (PROCESS);

ADIPOSE TISSUE; ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY WEIGHT; EPIDIDYMIS; GENE EXPRESSION PROFILING; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LEUKOCYTES; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; OSMOSIS; STILBENES;

EID: 84954531451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146840     Document Type: Article

References (54)

1. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annual review of immunology. 2011; 29:415-45. doi: 10.1146/annurev-immunol-031210-101322 PMID: 21219177.
2. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003; 52(3):812-7. PMID: 12606524.
3. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259(5091):87-91. PMID: 7678183.
4. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996; 271(5249):665-8. PMID: 8571133.
5. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulange A, Capeau J, et al. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia. 2006; 49(9):2162-73. doi: 10.1007/s00125-006-0335-z PMID: 16865359.
6. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology. 2005; 146(8):3417-27. doi: 10.1210/en.2004-1468 PMID: 15845623.
7. Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut. 2010; 59(9):1259-64. doi: 10.1136/gut.2010.214577 PMID: 20660075.
8. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56(7):1761-72. doi: 10.2337/db06-1491 PMID: 17456850.
9. Luche E, Cousin B, Garidou L, Serino M, Waget A, Barreau C, et al. Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanism. Mol Metab. 2013; 2(3):281-91. doi: 10.1016/j.molmet.2013.06.005 PMID: 24049740; PubMed Central PMCID: PMC3773833.
10. Nguyen AT, Mandard S, Dray C, Deckert V, Valet P, Besnard P, et al. Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes. 2014; 63(2):471-82. doi: 10.2337/db13-0903 PMID: 24186868.
11. Kahles F, Meyer C, Mollmann J, Diebold S, Findeisen HM, Lebherz C, et al. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes. 2014; 63(10):3221-9. doi: 10.2337/db14-0100 PMID: 24947356.
12. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006; 444(7117):337-42. Epub 2006/11/07. doi: 10.1038/nature05354 PMID: 17086191.
13. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006; 127(6):1109-22. Epub 2006/11/23. doi: 10.1016/j.cell.2006.11.013 PMID: 17112576.
14. Jimenez-Gomez Y, Mattison JA, Pearson KJ, Martin-Montalvo A, Palacios HH, Sossong AM, et al. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab. 2013; 18(4):533-45. doi: 10.1016/j.cmet. 2013.09.004 PMID: 24093677; PubMed Central PMCID: PMC3832130.
15. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism. 2011; 14(5):612-22. Epub 2011/11/08. doi: 10.1016/j.cmet.2011. 10.002 PMID: 22055504.
16. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebocontrolled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013; 62(4):1186-95. Epub 2012/11/30. doi: 10.2337/db12-0975 PMID: 23193181; PubMed Central PMCID: PMC3609591.
17. Knop FK, Konings E, Timmers S, Schrauwen P, Holst JJ, Blaak EE. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet Med. 2013; 30(10):1214-8. doi: 10.1111/dme.12231 PMID: 23663119.
18. Dao TM, Waget A, Klopp P, Serino M, Vachoux C, Pechere L, et al. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One. 2011; 6(6):e20700. Epub 2011/06/16. doi: 10.1371/journal.pone.0020700 PMID: 21673955; PubMed Central PMCID: PMC3108962.
19. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. 2000; 164(12):6509-19. PMID: 10843709.
20. Heynekamp JJ, Weber WM, Hunsaker LA, Gonzales AM, Orlando RA, Deck LM, et al. Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappaB. J Med Chem. 2006; 49 (24):7182-9. doi: 10.1021/jm060630x PMID: 17125270.
21. Sebai H, Ben-Attia M, Sani M, Aouani E, Ghanem-Boughanmi N. Protective effect of resveratrol in endotoxemia-induced acute phase response in rats. Arch Toxicol. 2009; 83(4):335-40. doi: 10.1007/s00204-008-0348-0 PMID: 18754105.
22. Sebai H, Sani M, Ghanem-Boughanmi N, Aouani E. Prevention of lipopolysaccharide-induced mouse lethality by resveratrol. Food Chem Toxicol. 2010; 48(6):1543-9. doi: 10.1016/j.fct.2010.03.022 PMID: 20304025.
23. Larrosa M, Azorin-Ortuno M, Yanez-Gascon MJ, Garcia-Conesa MT, Tomas-Barberan F, Espin JC. Lack of effect of oral administration of resveratrol in LPS-induced systemic inflammation. Eur J Nutr. 2011; 50(8):673-80. doi: 10.1007/s00394-011-0178-3 PMID: 21373948.
24. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012; 15(5):675-90. doi: 10.1016/j.cmet.2012.04.003 PMID: 22560220; PubMed Central PMCID: PMC3545644.
25. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010; 59(3):554-63. doi: 10.2337/db09-0482 PMID: 19934007; PubMed Central PMCID: PMC2828647.
26. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012; 148(3):421-33. doi: 10.1016/j. cell.2012.01.017 PMID: 22304913; PubMed Central PMCID: PMCPMC3431801.
27. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23(12):2369-80. doi: 10.1038/sj.emboj.7600244 PMID: 15152190; PubMed Central PMCID: PMC423286.
28. Qiang L, Wang L, Kon N, Zhao W, Lee S, Zhang Y, et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppargamma. Cell. 2012; 150(3):620-32. doi: 10.1016/j.cell.2012.06. 027 PMID: 22863012; PubMed Central PMCID: PMC3413172.
29. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. American journal of physiology Endocrinology and metabolism. 2008; 295(6):E1323-32. Epub 2008/09/25. doi: 10.1152/ajpendo.90617.2008 PMID: 18812462.
30. Arvidsson S, Kwasniewski M, Riano-Pachon DM, Mueller-Roeber B. Quant Prime-a flexible tool for reliable high-throughput primer design for quantitative PCR. BMC Bioinformatics. 2008; 9:465. doi: 10.1186/1471-2105-9-465 PMID: 18976492; PubMed Central PMCID: PMC2612009.
31. Moller AB, Vendelbo MH, Christensen B, Clasen BF, Bak AM, Jorgensen JO, et al. Physical exercise increases autophagic signaling through ULK1 in human skeletal muscle. J Appl Physiol (1985). 2015; 118(8):971-9. doi: 10.1152/japplphysiol.01116.2014 PMID: 25678702.
32. Radko Y, Christensen KB, Christensen LP. Semi-preparative isolation of dihydroresveratrol-3-O-betad-glucuronide and four resveratrol conjugates from human urine after oral intake of a resveratrol-containing dietary supplement. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 930:54-61. doi: 10.1016/j.jchromb.2013.05.002 PMID: 23727867.
33. Tura A, Kautzky-Willer A, Pacini G. Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. Diabetes Res Clin Pract. 2006; 72(3):298-301. doi: 10.1016/j.diabres.2005.10.005 PMID: 16325298.
34. Seltzer HS, Allen EW, Herron AL Jr., Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967; 46(3):323-35. doi: 10.1172/JCI105534 PMID: 6023769; PubMed Central PMCID: PMC297053.
35. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7(8):941-6. doi: 10.1038/90984 PMID: 11479627.
36. Thiebaud D, Jacot E, DeFronzo RA, Maeder E, Jequier E, Felber JP. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes. 1982; 31 (11):957-63. PMID: 6757014.
37. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007; 87(4):1409-39. doi: 10.1152/physrev.00034.2006 PMID: 17928588.
38. Investigators N-SS, Finfer S, Liu B, Chittock DR, Norton R, Myburgh JA, et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med. 2012; 367(12):1108-18. doi: 10.1056/NEJMoa1204942 PMID: 22992074.
39. De La Rosa G, Vasquez EM, Quintero AM, Donado JH, Bedoya M, Restrepo AH, et al. The potential impact of admission insulin levels on patient outcome in the intensive care unit. J Trauma Acute Care Surg. 2013; 74(1):270-5. doi: 10.1097/TA.0b013e3182788042 PMID: 23271103.
40. Brix-Christensen V, Andersen SK, Andersen R, Mengel A, Dyhr T, Andersen NT, et al. Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: an experimental study in a porcine model. Anesthesiology. 2004; 100(4):861-70. PMID: 15087621.
41. Jeschke MG, Klein D, Bolder U, Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology. 2004; 145(9):4084-93. doi: 10.1210/en.2004-0592 PMID: 15192048.
42. Kidd LB, Schabbauer GA, Luyendyk JP, Holscher TD, Tilley RE, Tencati M, et al. Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther. 2008; 326(1):348-53. doi: 10.1124/jpet.108.138891 PMID: 18445780; PubMed Central PMCID: PMC2836781.
43. Caesar R, Reigstad CS, Backhed HK, Reinhardt C, Ketonen M, Lunden GO, et al. Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut. 2012; 61(12):1701-7. doi: 10.1136/gutjnl-2011-301689 PMID: 22535377; PubMed Central PMCID: PMC3505865.
44. Olholm J, Paulsen SK, Cullberg KB, Richelsen B, Pedersen SB. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes (Lond). 2010; 34 (10):1546-53. doi: 10.1038/ijo.2010.98 PMID: 20531350.
45. Cullberg KB, Olholm J, Paulsen SK, Foldager CB, Lind M, Richelsen B, et al. Resveratrol has inhibitory effects on the hypoxia-induced inflammation and angiogenesis in human adipose tissue in vitro. Eur J Pharm Sci. 2013; 49(2):251-7. doi: 10.1016/j.ejps.2013.02.014 PMID: 23466666.
46. Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol. 2001; 62(9):1299-308. PMID: 11705464.
47. Pouliot MC, Despres JP, Nadeau A, Moorjani S, Prud'Homme D, Lupien PJ, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes. 1992; 41 (7):826-34. PMID: 1612197.
48. Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring). 2010; 18(11):2191-8. doi: 10.1038/oby.2010.59 PMID: 20339361; PubMed Central PMCID: PMCPMC3033570.
49. Garidou L, Pomie C, Klopp P, Waget A, Charpentier J, Aloulou M, et al. The Gut Microbiota Regulates Intestinal CD4 T Cells Expressing RORgammat and Controls Metabolic Disease. Cell Metab. 2015; 22 (1):100-12. doi: 10.1016/j.cmet.2015.06.001 PMID: 26154056.
50. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50(9):2094-9. PMID: 11522676.
51. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2002; 290(3):1084-9. doi: 10.1006/bbrc.2001.6307 PMID: 11798186.
52. Kang L, Heng W, Yuan A, Baolin L, Fang H. Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: Relative to inhibition of inflammatory responses. Biochimie. 2010; 92 (7):789-96. doi: 10.1016/j.biochi.2010.02.024 PMID: 20188786.
53. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, et al. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab. 2003; 285(5):E1072-80. doi: 10.1152/ajpendo.00206.2003 PMID: 12876073.
54. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004; 219(1-2):9-15. doi: 10.1016/j.mce.2004.03.002 PMID: 15149722.